Abstract Global pharma revenue is expected to reach around $1.1-1.3 trillion dollars in the next few years. Even
with increasing global effluence affordability remains an issue. High priced drugs can deliver the revenue
but very few can afford them even in mutually subsidized systems.
Demand dictates API manufacturing process and formulation technologies. Pharmaceutical companies have to take the lead
through use of best technologies to make drugs affordable to larger population. Unless industry takes the lead billions will be spent by
very limited patient base.
Pharma has to internalize technology innovation and wider use of drugs. At current pricing strategies less than 1% of the global
population will benefit from new the drugs. Regulatory bodies cannot force change and unless pharma takes the lead it will be stuck
in “analysis paralysis’ mode.